The Anti-CSF2/GM-CSF Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the cytokine CSF2, also known as granulocyte-macrophage colony-stimulating factor (GM-CSF), playing a crucial role in immune system regulation by stimulating the production of white blood cells. This antibody is comprised of a human IgG1-type heavy chain and a human lambda-type light chain, with a predicted molecular weight of 145.02 kDa. For experimental controls, it is recommended to use Human IgG1 kappa, Isotype Control, which serves as an appropriate isotype control for this antibody. This product is essential for research focused on immunology, inflammation, and potential therapeutic interventions involving GM-CSF.
The Anti-CSF2/GM-CSF Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the cytokine CSF2, also known as granulocyte-macrophage colony-stimulating factor (GM-CSF), playing a crucial role in immune system regulation by stimulating the production of white blood cells. This antibody is comprised of a human IgG1-type heavy chain and a human lambda-type light chain, with a predicted molecular weight of 145.02 kDa. For experimental controls, it is recommended to use Human IgG1 kappa, Isotype Control, which serves as an appropriate isotype control for this antibody. This product is essential for research focused on immunology, inflammation, and potential therapeutic interventions involving GM-CSF.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
